Abstract
The cyclopeptolide CAM741 inhibits cotranslational translocation of vascular cell adhesion molecule 1 (VCAM1), which is dependent on its signal peptide. We now describe the identification of the signal peptide of vascular endothelial growth factor (VEGF) as the second target of CAM741. The mechanism by which the compound inhibits translocation of VEGF is very similar or identical to that of VCAM1, although the signal peptides share no obvious sequence similarities. By mutagenesis of the VEGF signal peptide, two important regions, located in the N-terminal and hydrophobic segments, were identified as critical for compound sensitivity. CAM741 alters positioning of the VEGF signal peptide at the translocon, and increasing hydrophobicity in the h-region reduces compound sensitivity and causes a different, possibly more efficient, interaction with the translocon. Although CAM741 is effective against translocation of both VEGF and VCAM1, the derivative NFI028 is able to inhibit only VCAM1, suggesting that chemical derivatization can alter not only potency, but also the specificity of the compounds.
Footnotes
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.107.034249.
-
ABBREVIATIONS: VCAM1, vascular cell adhesion molecule 1; SP, signal peptide; ER, endoplasmic reticulum; VEGF, vascular endothelial growth factor-A; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; ELISA, enzyme-linked immunosorbent assay; TGF-α, transforming growth factor-α; SEAP, secreted alkaline phosphatase; HEK, human embryonic kidney; NC, nascent chain; wt, wild-type; MBS, m-maleimidobenzoyl-N-hydroxysuccinimide ester; BMH, bis-maleimidohexane; HUN-7293, cyclo[N-methyl-l-alanyl-(2R)-4-cyano-2-hydroxybutanoyl-(2S,4R)-2-amino-4-methyloctanoyl-N-methyl-l-leucyl-l-leucyl-1-methoxy-N-methyl-l-tryptophyl-(2S,4R)-2-amino-4-methyloctanoyl].
- Received January 19, 2007.
- Accepted March 16, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|